Latest Conference Articles

Families of children with acute lymphoblastic leukemia face significant financial challenges during treatment, with many experiencing material hardship and income loss.

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

The MajesTEC-3 trial showed that teclistamab combined with subcutaneous daratumumab improved overall survival vs standard daratumumab-based regimens in relapsed/refractory multiple myeloma.

Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.

A new triplet therapy combining tagraxofusp, azacitidine, and venetoclax shows promising response rates and transplant potential for BPDCN patients.

The KOMET-007 trial reveals promising safety and efficacy of ziftomenib combined with venetoclax and azacitidine for relapsed/refractory AML patients.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

The MagnetisMM-30 trial reveals promising early responses and manageable safety for elranatamab and iberdomide in relapsed multiple myeloma patients.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.

A recent study reveals that Black patients with acute myeloid leukemia face significantly poorer survival rates compared to White patients, highlighting racial disparities in treatment outcomes.

Cilta-cel shows promising long-term survival rates in relapsed/refractory multiple myeloma, suggesting potential for a cure in standard-risk patients.

A new combination therapy shows promising results in achieving durable remission for patients with NPM1-mutated acute myeloid leukemia.

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Bispecific antibodies talquetamab and teclistamab show promising results in treating relapsed/refractory multiple myeloma with extramedullary disease, achieving high response rates.

Discover the nuances of CAR T-cell therapy eligibility and its advantages over traditional chemotherapy for long-term patient outcomes.

NXC-201 CAR T-cell therapy shows promising results in treating relapsed AL amyloidosis, achieving deep responses and rapid normalization of disease markers.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

Long-term follow-up of the TRANSFORM study reveals liso-cel's impressive efficacy and safety in treating relapsed large B-cell lymphoma.

The SAVE regimen demonstrates promising efficacy in newly diagnosed AML, achieving high response rates but raises concerns about myelosuppression.

AZD0120 demonstrates impressive early efficacy and safety in treating relapsed/refractory multiple myeloma, with a 96% response rate and rapid manufacturing.

A promising trial reveals high response rates and survival outcomes for decitabine/cedazuridine and venetoclax in high-risk hematologic malignancies.

A phase 2 study reveals promising results for zanubrutinib combined with R-CHOP in treating untreated diffuse large B-cell lymphoma patients.

GLPG5101 shows promising efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma, achieving high response rates and rapid manufacturing.

Linvoseltamab shows promising efficacy and safety as a monotherapy for newly diagnosed multiple myeloma, offering a simpler treatment alternative.

Cevostamab shows promising efficacy and manageable safety in treating relapsed/refractory multiple myeloma, offering a convenient subcutaneous administration option.

New research highlights measurable residual disease (MRD) as a key predictor of survival in acute myeloid leukemia, potentially transforming treatment strategies.

A targeted therapy-first approach shows promise in reducing chemotherapy needs for newly diagnosed large B-cell lymphoma patients, maintaining high response rates.

Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.